Results 51 to 60 of about 122,587 (295)

The alcohol withdrawal syndrome

open access: yesAnnals of Emergency Medicine, 1982
Summary The alcohol withdrawal syndrome represents an acute medical emergency of probable multifactorial cause. The emergency physician who sees only one point in the spectrum of the patient's disease must be aware of the other clinical entities simulating its presentation.
openaire   +3 more sources

Modeling alcohol use disorder severity: An integrative structural equation modeling approach [PDF]

open access: yes, 2013
Background: Alcohol dependence is a complex psychological disorder whose phenomenology changes as the disorder progresses. Neuroscience has provided a variety of theories and evidence for the development, maintenance, and severity of addiction; however ...
Bacio, GA   +3 more
core   +2 more sources

Buprenorphine in Neonatal Abstinence Syndrome. [PDF]

open access: yes, 2018
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and ...
Kraft, Walter K.
core   +1 more source

Alcohol Withdrawal Syndrome

open access: yesInternational Journal of Medical Research and Review, 2016
Alcohol withdrawal syndrome is a cluster of symptoms occurring when someone detoxes from alcohol. Alcohol dependence is one of the commonest psychiatric disorders, second only to major depression.
Chandran, Rabindran, Gedam, D Sharad
openaire   +3 more sources

Comparison of two nicotine dependence measures for use with Korean American Women: The FTND and AUTOS

open access: yes, 2017
This study compares psychometric properties of the Fagerström Test for Nicotine Dependence (FTND) and Autonomy over Tobacco Scale (AUTOS), which are measures of nicotine dependence.
Kim, Sun S, PhD, APRN-BC
core   +1 more source

The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective [PDF]

open access: yes, 2019
© 2019 Orsolini, Chiappini, Papanti, De Berardis, Corkery and Schifano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Chiappini, Stephania   +5 more
core   +2 more sources

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman   +6 more
wiley   +1 more source

As Opioid Use Climbs, Neonatal Abstinence Syndrome Rises in New Hampshire [PDF]

open access: yes, 2017
In this brief, author Kristin Smith analyzes inpatient hospital discharge data (2012–2015) to assess the prevalence of neonatal abstinence syndrome (NAS) in New Hampshire; describes one hospital’s successful program for treating pregnant women and ...
Smith, Kristin
core   +1 more source

The genomics of neonatal abstinence syndrome [PDF]

open access: yes, 2017
Significant variability has been observed in the development and severity of neonatal abstinence syndrome (NAS) among neonates exposed to prenatal opioids.
Cole, F. Sessions   +2 more
core   +3 more sources

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy